Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

被引:188
|
作者
White, Ann L. [1 ]
Chan, H. T. Claude [1 ]
Roghanian, Ali [1 ]
French, Ruth R. [1 ]
Mockridge, C. Ian [1 ]
Tutt, Alison L. [1 ]
Dixon, Sandra V. [1 ]
Ajona, Daniel [1 ]
Verbeek, J. Sjef [2 ]
Al-Shamkhani, Aymen [1 ]
Cragg, Mark S. [1 ]
Beers, Stephen A. [1 ]
Glennie, Martin J. [1 ]
机构
[1] Univ Southampton, Fac Med, Div Canc Sci, Southampton SO16 6YD, Hants, England
[2] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZA Leiden, Netherlands
来源
JOURNAL OF IMMUNOLOGY | 2011年 / 187卷 / 04期
关键词
C-RECEPTOR POLYMORPHISMS; T-CELL TOLERANCE; IN-VIVO; CD20; IMMUNOTHERAPY; CD40; PATHWAY; B-CELLS; LYMPHOMA; CANCER; THERAPY; TUMOR;
D O I
10.4049/jimmunol.1101135
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A high activatory/inhibitory Fc gamma R binding ratio is critical for the activity of mAb such as rituximab and alemtuzumab that attack cancer cells directly and eliminate them by recruiting immune effectors. Optimal Fc gamma R binding profiles of other anti-cancer mAb, such as immunostimulatory mAb that stimulate or block immune receptors, are less clear. In this study, we analyzed the importance of isotype and Fc gamma R interactions in controlling the agonistic activity of the anti-mouse CD40 mAb 3/23. Mouse IgG1 (m1) and IgG2a (m2a) variants of the parental 3/23 (rat IgG2a) were engineered and used to promote humoral and cellular responses against OVA. The mouse IgG1 3/23 was highly agonistic and outperformed the parental Ab when promoting Ab (10-100-fold) and T cell (OTI and OTII) responses (2- to >10-fold). In contrast, m2a was almost completely inactive. Studies in Fc gamma R knockout mice demonstrated a critical role for the inhibitory Fc gamma RIIB in 3/23 activity, whereas activatory Fc gamma R (Fc gamma RI, -III, and -IV) was dispensable. In vitro experiments established that the stimulatory effect of Fc gamma RIIB was mediated through Ab cross-linking delivered in trans between neighboring cells and did not require intracellular signaling. Intriguingly, activatory Fc gamma R provided effective cross-linking of 3/23 m2a in vitro, suggesting the critical role of Fc gamma RIIB in vivo reflects its cellular distribution and bioavailability as much as its affinity for a particular Ab isotype. In conclusion, we demonstrate an essential cross-linking role for the inhibitory Fc gamma RIIB in anti-CD40 immunostimulatory activity and suggest that isotype will be an important issue when optimizing reagents for clinical use. The Journal of Immunology, 2011, 187: 1754-1763.
引用
收藏
页码:1754 / 1763
页数:10
相关论文
共 50 条
  • [21] The engineered agonistic anti-CD40 antibody potentiates the antitumor effects of β-glucan by resetting TAMs
    Cheng, Wanpeng
    Huang, Ziyi
    Hao, Yongzhe
    Hua, Hui
    Zhang, Bo
    Li, Xiangyang
    Fu, Fengqing
    Yang, Jing
    Zheng, Kuiyang
    Zhang, Xueguang
    Qi, Chunjian
    IMMUNOLOGY LETTERS, 2024, 268
  • [22] The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer
    Khong, Andrea
    Nelson, Delia J.
    Nowak, Anna K.
    Lake, Richard A.
    Robinson, Bruce W. S.
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2012, 31 (04) : 246 - 266
  • [23] Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
    Ishihara, Jun
    Ishihara, Ako
    Potin, Lambert
    Hosseinchi, Peyman
    Fukunaga, Kazuto
    Damo, Martina
    Gajewski, Thomas F.
    Swartz, Melody A.
    Hubbell, Jeffrey A.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (11) : 2399 - 2411
  • [24] Therapeutic activity of agonistic anti-CD40 mAb in a chronic autoimmune inflammatory process
    Mauri, C
    Mars, LT
    Londei, M
    FASEB JOURNAL, 2000, 14 (06): : A1101 - A1101
  • [25] Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells:: the Janus face of anti-CD40
    de Herve, MGD
    Durali, D
    Tran, TA
    Maigné, G
    Simonetta, F
    Leclerc, P
    Delfraissy, JF
    Taoufik, Y
    BLOOD, 2005, 106 (08) : 2806 - 2814
  • [26] Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models
    Shoji, Takuhiro
    Saito, Ryuta
    Chonan, Masashi
    Shibahara, Ichiyo
    Sato, Aya
    Kanamori, Masayuki
    Sonoda, Yukihiko
    Kondo, Toru
    Ishii, Naoto
    Tominaga, Teiji
    NEURO-ONCOLOGY, 2016, 18 (08) : 1120 - 1128
  • [27] T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
    Tutt, AL
    O'Brien, L
    Hussain, A
    Crowther, GR
    French, RR
    Glennie, MJ
    JOURNAL OF IMMUNOLOGY, 2002, 168 (06): : 2720 - 2728
  • [28] In Vivo Characterization of a Novel Recombinant Anti-CD40 Monoclonal Antibody in Nonhuman Primates
    Badell, I. R.
    Mendel, J. B.
    Robertson, J. M.
    Johnson, B. E.
    Wang, X.
    Wang, R.
    Iwakoshi, N. N.
    Reimann, K. A.
    Kirk, A. D.
    Larsen, Christian P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 214 - 214
  • [29] Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
    Richard J. Stopforth
    Kirstie L. S. Cleary
    Mark S. Cragg
    Journal of Clinical Immunology, 2016, 36 : 88 - 94
  • [30] Anti-CD40 monoclonal antibody therapy: Treatment toxicity and implications for cancer immunotherapy
    Geldart, T
    Harvey, M
    Carr, N
    Glennie, M
    Johnson, P
    BRITISH JOURNAL OF CANCER, 2003, 88 : S36 - S36